Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Trastuzumab Biosimilars Market In 2029?

The size of the trastuzumab biosimilars market has expanded significantly in the past few years. The market was worth $4.27 billion in 2024 and is projected to rise to $5.43 billion in 2025, showing a compound annual growth rate (CAGR) of 27.1%. The notable increase during the historic period is a result of factors such as extensive market expansion and global penetration, the expiration of patents and market entry, the swift development of biosimilars, the validation of clinical efficacy, and competitive pricing strategies.

What Growth Rate Is Forecasted for the Trastuzumab Biosimilars Market by 2029?

The market size for trastuzumab biosimilar is anticipated to experience a substantial surge in the near future, expanding to $14.69 billion by 2029 with a compound annual growth rate (CAGR) of 28.3%. The escalation during the projected period can be credited to factors such as heightened market competition, the progression of the biosimilar pipeline, regulatory consent and standardizations, global market invasion, as well as the adoption and prescribing habits of physicians. The prediction period will see major trends such as enhanced accessibility, market segmentation tactics, educational drives, patient leaning towards biosimilars, and physician approval.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3400&type=smp

Which Key Companies Are Shaping the Future of the Trastuzumab Biosimilars Market?

Major companies operating in the trastuzumab biosimilars market include Pfizer Inc., Merck & Co., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan NV, Fujifilm Kyowa Kirin Biologics Co. Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Apotex Inc., Samsung Bioepis Co. Ltd., Celltrion Inc., Zydus Lifesciences Limited, BIOCAD, Shanghai Henlius Biotech Inc., Biocon Limited, Alvotech Holdings S.A., Polpharma Biologics S.A, EirGenix Inc., Hetero Biopharma Limited, Mabion SA, ALTEOGEN Inc., Prestige BioPharma Limited, AryoGen Pharmed Co. Ltd., Intas Pharmaceuticals Limited, Glenmark Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Limited, Torrent Pharmaceuticals Limited

Which Factors Are Driving Demand in the Trastuzumab Biosimilars Industry?

The growing incidence of breast and stomach cancer has played a significant role in promoting the trastuzumab biosimilars market. Trastuzumab biosimilar is applied in treating human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic stomach cancer. The American Cancer Society, a US-based health organization intent on eradicating cancer, stated in September 2023, that approximately 297,790 fresh instances of invasive breast cancer are projected to occur in women in 2023, and about 43,700 women are estimated to succumb to breast cancer in the same year. Cancer India reports that breast cancer is the most prevalent cancer in Indian women, representing 14% of cancers in women. Hence, the escalating rates of breast and stomach cancer compound the demand for trastuzumab biosimilar, which is a cost-effective alternative to pricier medicines, stimulating the growth of the trastuzumab biosimilars market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3400&type=smp

How Is the Trastuzumab Biosimilars Market Segmented by Several Divisions?

The trastuzumab biosimilars market covered in this report is segmented –

1) By Product: Ogivri, Herzuma, Ontruzant, Trazimera, Other Products

2) By Indication: Adjuvant Breast Cancer, Metastatic Breast Cancer, Metastatic Gastric Cancer, Other Indications

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy

What are the Emerging Market Trends Driving the Growth of the Trastuzumab Biosimilars Industry?

The trastuzumab biosimilars market is being shaped by key players who are constantly launching new products in untapped regions. These companies are executing various strategic maneuvers like developing new products, forming partnerships, and expanding their geographic and product portfolios to retain market competitiveness and cater to customer needs better. For instance, in April 2024, US-based pharmaceutical firm Accord BioPharma Inc. secured approval from the U.S. Food and Drug Administration (FDA) for its biosimilar to Herceptin, known as HERCESSI (trastuzumab-strf), designed for treating multiple forms of HER2-Overexpressing Cancer. HERCESSI is principally prescribed for adjunctive treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric or gastroesophageal junction adenocarcinoma. Despite HER2-positive cancers being generally aggressive, they respond effectively to targeted treatments. By binding to the HER2 receptor, HERCESSI inhibits its activity, thereby slowing the cancer cell reproduction.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Which Regions Are Driving Growth in the Trastuzumab Biosimilars Market?

The countries covered in the trastuzumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3400

This Report Delivers Insight On:

1. How big is the trastuzumab biosimilars market, and how is it changing globally?

2. Who are the major companies in the trastuzumab biosimilars market, and how are they performing?

3. What are the key opportunities and risks in the trastuzumab biosimilars market right now?

4. Which products or customer segments are growing the most in the trastuzumab biosimilars market?

5. What factors are helping or slowing down the growth of the trastuzumab biosimilars market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model